Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study

被引：0
|
作者：
Kuemmel, Sherko [1 ,2 ]
Schmid, Peter [3 ]
Harbeck, Nadia [4 ]
Takahashi, Masato [5 ]
Untch, Michael [6 ]
Boileau, Jean-Francois [7 ]
Cortes, Javier [8 ,9 ]
McArthur, Heather [10 ]
Dent, Rebecca [11 ]
O'Shaughnessy, Joyce [12 ]
Pusztai, Lajos [13 ]
Foukakis, Theodoros [14 ,15 ]
Park, Yeon Hee [16 ]
Hui, Rina [17 ,18 ]
Cardoso, Fatima [19 ]
Denkert, Carsten [20 ,21 ]
Zhu, Yalin [22 ]
Pan, Wilbur [22 ]
Karantza, Vassiliki [22 ]
Fasching, Peter A. [23 ]
机构：
[1] Kliniken Essen Mitte, Breast Unit, Essen, Germany
[2] Charite Univ Med Berlin, Dept Gynecol Breast Ctr, Berlin, Germany
[3] Queen Mary Univ London, Barts Canc Inst, London, England
[4] LMU Univ Hosp, Breast Ctr, Munich, Germany
[5] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[6] Helios Klinikum Berlin Buch, Breast Canc Ctr, Berlin, Germany
[7] McGill Univ, Jewish Gen Hosp Segal Canc Ctr, Montreal, PQ, Canada
[8] Quiron Grp, Int Breast Canc Ctr, Pangaea Oncol, Barcelona, Spain
[9] Univ Europea Madrid, Madrid, Spain
[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[11] Duke Natl Univ Singapore Med Sch, Natl Canc Ctr Singapore, Singapore, Singapore
[12] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[13] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[14] Karolinska Inst, Solna, Sweden
[15] Karolinska Univ Hosp, Breast Canc Ctr, Karolinska Comprehens Canc Ctr, Solna, Sweden
[16] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[17] Westmead Hosp, Westmead Breast Canc Inst, Sydney, NSW, Australia
[18] Univ Sydney, Sydney, NSW, Australia
[19] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[20] Philipps Univ Marburg, Inst Pathol, Marburg, Germany
[21] Univ Hosp Marburg, Marburg, Germany
[22] Merck & Co Inc, Rahway, NJ USA
[23] Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1462344
引用
收藏
页码：S295 / S296
页数：2
相关论文
共 50 条
  • [31] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
    Bang, Y-J.
    Van Cutsem, E.
    Fuchs, C. S.
    Ohtsu, A.
    Tabernero, J.
    Ilson, D. H.
    Hyung, W. J.
    Strong, V. E.
    Goetze, T. O.
    Yoshikawa, T.
    Tang, L. H.
    Hwang, P. M. T.
    Adelberg, D.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 268 - 268
  • [32] Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
    Shitara, K.
    Rha, S. Y.
    Wyrwicz, L. S.
    Oshima, T.
    Karaseva, N.
    Osipov, M.
    Yasui, H.
    Yabusaki, H.
    Afanasyev, S.
    Park, YK.
    Al-Batran, SE.
    Yoshikawa, T.
    Weber, P. E. Yanez
    Di Bartolomeo, M.
    Lonardi, S.
    Fang, X.
    Shih, CS.
    Bhagia, P.
    Bang, YJ.
    ANNALS OF ONCOLOGY, 2023, 34 : S1316 - S1316
  • [33] Pembrolizumab plus Olaparib vs Pembrolizumab plus Chemotherapy After Induction With Pembrolizumab plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
    Rugo, Hope
    Robson, Mark
    Im, Seock-Ah
    Dalenc, Florence
    Ruiz, Eduardo Yanez
    Im, Young-Hyuck
    Kulyk, Sergii
    Dudnichenko, Oleksandr
    Llinas-Quintero, Nestor
    Saji, Shigehira
    Miyoshi, Yasuo
    Harbeck, Nadia
    Fan, Li
    Mejia, Jaime
    Karantza, Vassiliki
    Cescon, David
    CANCER RESEARCH, 2024, 84 (09)
  • [34] KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K.
    Salman, P.
    Usta, E. Hoyos
    Yanez, E.
    Gumus, M.
    de Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S.
    Monk, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A364 - A364
  • [35] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
    Spicer, Jonathan D.
    Garassino, Marina C.
    Wakelee, Heather
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    Chen, Ke-Neng
    Dooms, Christophe
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston L.
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Arunachalam, Ashwini
    Keller, Steven M.
    Samkari, Ayman
    Gao, Shugeng
    LANCET, 2024, 404 (10459): : 1240 - 1252
  • [36] KEYNOTE-590: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, Ken
    Shah, Manish
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Zhu, Ying
    Bhagia, Pooja
    Koshiji, Minori
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [37] Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
    Cescon, David W.
    Schmid, Peter
    Rugo, Hope S.
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Haiderali, Amin
    Zhou, Xuan
    Guo, Zifang
    Nguyen, Allison Martin
    Cortes, Javier
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (05): : 717 - 727
  • [38] Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585
    Shitara, Kohei
    Bang, Yung-Jue
    Wyrwicz, Lucjan S.
    Rha, Sun Young
    Oshima, Takashi
    Di Bartolomeo, Maria
    Park, Young-Kyu
    Lonardi, Sara
    Weber, Patricio Eduardo Yanez
    Yen, Chia-Jui
    Metges, Jean-Philippe
    Garrido, Marcelo
    Moehler, Markus H.
    Pelles-Avraham, Sharon
    Yong, Wei-Peng
    Spallanzani, Andrea
    Jensen, Erin
    Krishnan, Radha
    Shih, Chie-Schin
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A phase 3 study of chemotherapy 1 pembrolizumab vs chemotherapy 1 placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585-Trial in progress
    Bang, Y.
    Van Cutsem, E.
    Fuchs, C.
    Ohtsu, A.
    Tabernero, J.
    Ilson, D.
    Hyung, W.
    Strong, V.
    Goetze, T.
    Yoshikawa, T.
    Tang, L.
    Hwang, P.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
    Levy, B.
    Giaccone, G.
    Besse, B.
    Felip, E.
    Garassino, M.
    Domine, M.
    Garrido, P.
    Piperdi, B.
    Ponce Aix, S.
    Slepetis, R.
    Wu, X.
    Fandi, A.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1803 - S1804
12345